408 related articles for article (PubMed ID: 28794805)
1. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations.
In GK; Hu JS; Tseng WW
Ther Adv Med Oncol; 2017 Aug; 9(8):533-550. PubMed ID: 28794805
[TBL] [Abstract][Full Text] [Related]
2. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
[TBL] [Abstract][Full Text] [Related]
3. Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin.
Kawai A; Yonemori K; Takahashi S; Araki N; Ueda T
Adv Ther; 2017 Jul; 34(7):1556-1571. PubMed ID: 28547734
[TBL] [Abstract][Full Text] [Related]
4. Advances of systemic treatment for adult soft-tissue sarcoma.
Liu W; Jiang Q; Zhou Y
Chin Clin Oncol; 2018 Aug; 7(4):42. PubMed ID: 30173532
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan.
Nakamura T; Asanuma K; Hagi T; Sudo A
Drug Des Devel Ther; 2020; 14():4215-4220. PubMed ID: 33116409
[TBL] [Abstract][Full Text] [Related]
6. The Role of Trabectedin in Soft Tissue Sarcoma.
Nakamura T; Sudo A
Front Pharmacol; 2022; 13():777872. PubMed ID: 35281940
[No Abstract] [Full Text] [Related]
7. Contemporary management of metastatic soft tissue sarcoma.
Bui NQ; Wang DS; Hiniker SM
Curr Probl Cancer; 2019 Aug; 43(4):289-299. PubMed ID: 31248634
[TBL] [Abstract][Full Text] [Related]
8. Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma.
Kopp HG; Patel S; Brücher B; Hartmann JT
Am J Clin Dermatol; 2008; 9(4):207-17. PubMed ID: 18572972
[TBL] [Abstract][Full Text] [Related]
9. Minimal Increase in Survival Throughout the Years in Patients with Soft Tissue Sarcoma with Synchronous Metastases: Results of a Population-Based Study.
Vos M; Ho VKY; Oosten AW; Verhoef C; Sleijfer S
Oncologist; 2019 Jul; 24(7):e526-e535. PubMed ID: 30190301
[TBL] [Abstract][Full Text] [Related]
10. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.
Tap WD; Wagner AJ; Schöffski P; Martin-Broto J; Krarup-Hansen A; Ganjoo KN; Yen CC; Abdul Razak AR; Spira A; Kawai A; Le Cesne A; Van Tine BA; Naito Y; Park SH; Fedenko A; Pápai Z; Soldatenkova V; Shahir A; Mo G; Wright J; Jones RL;
JAMA; 2020 Apr; 323(13):1266-1276. PubMed ID: 32259228
[TBL] [Abstract][Full Text] [Related]
11. Treating soft tissue sarcomas with adjuvant chemotherapy.
Patrikidou A; Domont J; Cioffi A; Le Cesne A
Curr Treat Options Oncol; 2011 Mar; 12(1):21-31. PubMed ID: 21384115
[TBL] [Abstract][Full Text] [Related]
12. Update on systemic therapy for advanced soft-tissue sarcoma.
Smrke A; Wang Y; Simmons C
Curr Oncol; 2020 Feb; 27(Suppl 1):25-33. PubMed ID: 32174755
[TBL] [Abstract][Full Text] [Related]
13. First-Line Therapy for Metastatic Soft Tissue Sarcoma.
Meyer M; Seetharam M
Curr Treat Options Oncol; 2019 Jan; 20(1):6. PubMed ID: 30675651
[TBL] [Abstract][Full Text] [Related]
14. Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival.
Thomas C; Movva S
Onco Targets Ther; 2016; 9():5619-27. PubMed ID: 27672333
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy.
Davis EJ; Chugh R
Drug Des Devel Ther; 2017; 11():3579-3587. PubMed ID: 29263653
[TBL] [Abstract][Full Text] [Related]
16. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
17. Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma.
Pender A; Jones RL
Clin Pharmacol; 2017; 9():159-164. PubMed ID: 29270033
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial.
Karch A; Koch A; Grünwald V
Trials; 2016 Jul; 17(1):312. PubMed ID: 27387325
[TBL] [Abstract][Full Text] [Related]
19. Analysis of clinical factors associated with survival in patients with soft-tissue sarcoma receiving trabectedin.
Simetić L; Blažičević K; Ladenhauser T; Golčić M; Majnarić T; Herceg D
Anticancer Drugs; 2021 Nov; 32(10):1058-1066. PubMed ID: 34232944
[TBL] [Abstract][Full Text] [Related]
20. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
Tap WD; Jones RL; Van Tine BA; Chmielowski B; Elias AD; Adkins D; Agulnik M; Cooney MM; Livingston MB; Pennock G; Hameed MR; Shah GD; Qin A; Shahir A; Cronier DM; Ilaria R; Conti I; Cosaert J; Schwartz GK
Lancet; 2016 Jul; 388(10043):488-97. PubMed ID: 27291997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]